Identifying systemic safety signals following intravitreal bevacizumab: Systematic review of the literature and the Canadian Adverse Drug Reaction Database

Canadian Journal of Ophthalmology

Volumn 45, Issue 3, 2010, Pages 231-238

  Micieli, Jonathan A ^a   Micieli, Andrew ^b   Smith, Andrew F ^c,d  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Medmetrics Inc   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Antiangiogenic therapy; Bevacizumab; Pharmacovigilance; Systematic literature review; Vascular endothelial growth factor

Indexed keywords

AZATHIOPRINE; BEVACIZUMAB; CEFALEXIN; FAMCICLOVIR; HYDROCHLOROTHIAZIDE; PREDNISONE; TELMISARTAN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ABDUCENS NERVE PARALYSIS; ABORTION; AMNESIA; CANADA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CINAHL; CLINICAL STUDY; CLINICAL TRIAL; COCHRANE LIBRARY; DATA BASE; DIABETIC MACULAR EDEMA; DISEASE ASSOCIATION; DRUG ERUPTION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EMBASE; HEALTH SURVEY; HEART INFARCTION; HUMAN; HYPERTENSION; INFORMATION SYSTEM; INTERNET; MEDLINE; METRORRHAGIA; NERVE PARALYSIS; NEUROLOGIC DISEASE; PUSTULE; RASH; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; TRANSIENT GLOBAL AMNESIA; ANTAGONISTS AND INHIBITORS; FACTUAL DATABASE; INJECTION; VITREOUS BODY;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CANADA; DATABASES, FACTUAL; HUMANS; INJECTIONS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 77953299956     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/i10-027     Document Type: Review

References (51)

1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431
2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444 (Pubitemid 44511558)
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342
4. Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol 2009;54:372-400.
5. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:3697-3705
6. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96:1788-1795 (Pubitemid 46912024)
7. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-859
8. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114:2179-2182
9. Csaky K, Do DV. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal antivascular endothelial growth factor therapies. Am J Ophthalmol 2009;148:647-656
10. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349 (Pubitemid 44702055)
11. Ladas ID, Karagiannis DA, Rouvas AA, Kotsolis AI, Liotsu A, Vergados I. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina 2009;29:313-318
12. Roth DB, King A, Weiss M, Klein D. Systemic adverse events after bevacizumab. Ophthalmology 2009;116:1226.e1.
13. Shima C, Sakaguchi H, Gomi F, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Opthalmol 2008;86:372-376
14. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-87
15. Wong LJ, Desai RU, Jain A, et al. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Retina 2008;28:1151-1158
16. Quiroz-Mercado H, Ustariz-González O, Martinez-Castellanos MA, Covarrubias P, Dominguez F, Sanchez-Huerta V. Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story. Semin Ophthalmol 2007;22:109-125 (Pubitemid 46918882)
17. Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 2007;143:510-512 (Pubitemid 46298546)
18. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007;27:133-140 (Pubitemid 46245638)
19. Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007;245:68-73. (Pubitemid 46766732)
20. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114:1179-1185 (Pubitemid 46829388)
21. Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-1867
22. Soheilian M, Ramezani A, Obudi A, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009;116:1142-1150
23. Kook D, Wolf A, Kreutzer T, et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina 2008;28:1053-1060
24. Fong KC, Kirkpatrick N, Mohamed Q, Johnston RL. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment. Clin Experiment Ophthalmol 2008;36:748-755
25. Cleary CA, Jungkim S, Ravikumar K, Kelliherc C, Archeson RW, Hickey-Dwyer M. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Eye 2008;22:82-86
26. Madhusudhana KC, Hannan SR, Williams CP, et al. Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases. Br J Ophthalmol 2007;91:1716-1717 (Pubitemid 350207411)
27. Kaiser PK. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2009;116:747-55.e1.
28. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-390 (Pubitemid 44197628)
29. Mekjavic PJ, Kraut A, Urbancic M, Lenassi E, Hawlina M. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections. Acta Ophthalmol 2009 Oct 23; [Epub ahead of print].
30. Arevalo JF, Sanchez JG, Fromow-Guerra J, et al. Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol 2009;247:735-743
31. Arevalo JF, Sanchez JG, Wu L, et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema. The Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 2009;116:1488-97.e1.
32. Amselem L, Diaz-Llopis M, Garcia-Delpech S, Montero J, Palomares P, Cervera E. Papulopustular eruption after intravitreal bevacizumab (Avastin). Acta Ophthalmol 2009;87:110-111
33. Micieli JA, Santiago P, Brent MH. Third nerve palsy following intravitreal anti-VEGF therapy for bilateral neovascular age-related macular degeneration. Acta Ophthalmol 2009 Nov 19; [Epub ahead of print].
34. Park HJ, Guy J. Sixth nerve palsy post intravitreal bevacizumab for AMD: a new possibly causal relationship and complication? Binocul Vis Strabismus Q 2007;22:209.
35. Byeon SH, Kwon OW, Lee SC. Transient global amnesia following intravitreal injection of bevacizumab. Acta Ophthalmol 2009;87:570.
36. Petrou P, Georgalas I, Giavaras G, Anastasiou E, Ntana Z, Petrou C. Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmol 2009 Sept 9; [Epub ahead of print].
37. Rodrigues EB, Shiroma H, Meyer CH, Maia M, Farah ME. Metrorrhagia after intravitreal injection of bevacizumab. Acta Ophthalmol Scand 2007;85:915-916
38. Wise L, Parkinson J, Raine J, Breckenridge A. New approaches to drug safety: a pharmacovigilance tool kit. Nat Rev Drug Discov 2009;8:779-782
39. Ziemssen F, Zhu Q, Peters S, et al. Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study. Int Ophthalmol 2009;29:213-224
40. Cousins S, Csaky K. Vascular Endothelial Growth Factor (VEGF) inhibitors in the treatment of choroidal neovascularization secondary to age-related macular degeneration. Snell Medical Communication 2009.
41. (Based on Csaky KF. Bevacizumab: it is not the same as ranibizumab. Presented at Current and Emerging Therapies in the Management of Age-related Neovascular Macular Degeneration. Nov 22, 2008, Edmonton, Alta.)
42. Ceyhan M, Günaydin S, Yorgancioglu C, Zorlutuna Y, Uluoglu C, Zengil H. Comparison of circadian rhythm characteristics of blood pressure and heart rate in patients before and after elective coronary artery bypass surgery. Chronobiol Int 2003;20:337-349 (Pubitemid 36505404)
43. Staessen JA, Asmar R, De Buyzere M, et al. Task Force II: blood pressure measurement and cardiovascular outcome. Blood Press Monit 2001;6:355-370 (Pubitemid 34194893)
44. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572
45. Micieli JA, Surkont M, Smith AF, et al. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Am J Ophthalmol 2009;148:536-43.e2.
46. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 2000;12:1232-1235
47. Mateo I, Llorca J, Infante J, et al. Low serum VEGF levels are associated with Alzheimer's disease. Acta Neurol Scand 2007;116:56-58 (Pubitemid 46976267)
48. Yang B, Lin P, Carrick KM, et al. PPARgamma agonists diminish serum VEGF elevation in diet-induced insulin resistant SD rats and ZDF rats. Biochem Biophys Res Commun 2005;334:176-182
49. Schmitt-Egenolf M. PsoReg - the Swedish registry for systemic psoriasis treatment. The registry's design and objectives. Dermatology 2007;214:112-117
50. Watson K, Symmons D, Griffiths I, Silman A. The British Society for Rheumatology biologics register. Ann Rheum Dis 2005;64 Suppl 4:iv42-3.
51. Zink A, Askling J, Dixon WG, Klareskog L, Silman AJ, Symmons DP. European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis 2009; 68:1240-1246